Pharming Group (OTCMKTS:PHGUF) Rating Lowered to Sell at Zacks Investment Research

Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, January 10th.

According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

A number of other research firms have also recently weighed in on PHGUF. HC Wainwright reiterated a “buy” rating on shares of Pharming Group in a research note on Thursday, October 26th. ValuEngine cut shares of Pharming Group from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.

Pharming Group (PHGUF) traded down $0.07 during trading hours on Wednesday, hitting $1.80. 4,500 shares of the stock traded hands, compared to its average volume of 78,774. Pharming Group has a one year low of $0.30 and a one year high of $1.96. The company has a market capitalization of $1,020.00 and a P/E ratio of -16.36. The company has a current ratio of 1.31, a quick ratio of 0.99 and a debt-to-equity ratio of 11.47.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/03/pharming-group-phguf-rating-lowered-to-sell-at-zacks-investment-research.html.

Pharming Group Company Profile

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.

Get a free copy of the Zacks research report on Pharming Group (PHGUF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply